Hims and Hers Offers Peptides and Cuts Forecast
Hims and Hers plans to offer unapproved peptide treatments following eased US regulations. Meanwhile, the company lowered its full-year profit forecast due to higher costs from branded weight-loss drugs.
Xurve View
Insights:
Xurve View
Hims & Hers Health will launch unapproved peptide treatments in November following updated regulatory enforcement discretion in the United States. The tele-health provider also cut its full-year core profit forecast on Monday as margins face pressure from higher costs. The strategic pivot toward branded weight-loss drugs and international expansion is reshaping the company's financial profile.
